A Randomized Trial of Heparin vs Placebo in Patients Undergoing Cardiac Catheterization Via the Trans-radial Approach

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's2 个研究点分布在 1 个国家目标入组 1,623 人2020年10月5日

适应症Cardiac Disease

干预措施Heparin Placebos

概览

阶段: 3 期
干预措施: Heparin
疾病 / 适应症: Cardiac Disease
发起方: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
入组人数: 1623
试验地点: 2
主要终点: radial artery occlusion
状态: 招募中
最后更新: 2个月前

概览研究者入排标准研究组 & 干预措施结局指标研究点相似试验

概览

简要总结

Patients undergoing cardiac catheterization will be randomized to 3 groups: no anticoagulant, low dose anticoagulant and high dose anticoagulant.

详细描述

Patients undergoing diagnostic cardiac catheterization via the trans-radial approach will be randomly allocated (1:1:1) to receive either low-dose UFH (25 IU/Kg -maximal dose 3,000 IU), high-dose UFH 50 IU/kg -maximal dose 5,000 IU) or N/S 0.9%. After 30 minutes, patients will undergo a gradual wrist band release. Hematoma and radial artery occlusion will be assessed.

注册库

clinicaltrials.gov

开始日期

2020年10月5日

结束日期

2026年12月1日

最后更新

2个月前

研究类型

Interventional

研究设计

Parallel

性别

All

研究者

发起方

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

责任方

Sponsor

入排标准

入选标准

•diagnostic cardiac catheterization; Small size sheath; patency of the ulno-palmar circulation

排除标准

•abnormal ulno-palmar circulation; Prior radial artery thrombosis; Prior surgery close to the access site; Emergent cardiac catheterization; History of HIT or allergy to heparin; Patients requiring anticoagulation